- Home
- WWR vs INKT Comparison
WWR vs INKT Comparison
Compare WWR & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WWR | INKT |
|---|---|---|
| Founded | 1977 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 59.4M |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WWR | INKT |
|---|---|---|
| Price | $0.47 | $12.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.17 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 685.4K | 17.4K |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $8.48 |
| 52 Week High | $3.75 | $15.35 |
Technical Indicators
Market Signals| Indicator | WWR | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 53.65 |
| Support Level | $0.48 | $10.84 |
| Resistance Level | $0.51 | $12.35 |
| Average True Range (ATR) | 0.03 | 0.66 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 15.78 | 52.80 |
Price Performance
Historical ComparisonAbout WWR Westwater Resources Inc.
Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.